Every major U.S. cancer center is short of at least one drug — and one in five is short of five or more

Drug shortages usually reach the public as an abstraction — a supply chain story, a manufacturing story, a story about a plant in another country. In oncology it is not abstract, because the treatment is a schedule. Chemotherapy works on intervals, and an interval that slips is a dose that changes.

So the number to sit with from this survey is not the percentage. It is the fact that every single center reported a shortage of at least one medicine.

What a "work-around" actually is

The phrase is doing a lot of quiet work, and it covers four very different situations. As a patient you are entitled to know which one applies to you.

Substitution. A different drug in the same class. Sometimes clinically equivalent, sometimes second-line — meaning it was not the first choice for a reason.

Dose rounding or vial sharing. Pharmacies stretch supply by adjusting doses to available vial sizes or splitting vials across patients. Usually invisible and usually fine, but it is a change.

Rescheduling. Pushing a cycle out days or a week to wait for supply. For some regimens that is tolerable. For others, interval is part of how the drug works.

Rationing by prognosis. The one nobody puts in a press release. When supply cannot cover everyone, centers set criteria for who gets the scarce drug — usually favoring curative intent over palliative. Ethics committees exist for this and it is done carefully, but it is a decision being made about you, not with you.

The clinical trials line is not a footnote

A majority of centers reporting disrupted trials matters for two groups of people.

For patients in a trial now, a supply interruption can mean coming off protocol — which sometimes means losing access to a drug that was working and cannot be obtained any other way.

For everyone else, it is a delay in the pipeline. A trial that pauses is a result that arrives a year later, and in oncology a year of evidence is a real quantity of life.

Why this keeps happening

The chronic answer is that most drugs in short supply are old, generic and injectable — the least profitable category in pharmaceuticals. Margins are thin enough that few manufacturers make each one, plants are old, and there is no financial reward for redundancy. One facility going offline for quality problems can empty the national supply of a drug that has been curing people since the 1970s.

That structure has not changed, which is why this survey looks a lot like the last one.

What to ask, and when

You cannot fix a supply chain from an infusion chair. You can make sure a change to your treatment is a decision rather than a surprise.

Ask at the start of a regimen: "Are any of the drugs in my plan currently in short supply here?" Asking before there is a problem is far more useful than asking after.

If something changes, ask what kind of change it is. Different drug, different dose, or different date — those are three separate conversations with three separate risks.

If a substitution is proposed, ask the comparison question: "How does this compare to the original in effectiveness and side effects for my specific cancer?" A center that has thought it through will have an answer ready.

If your cycle is delayed, ask what the delay costs. For some regimens, nothing. For others, dose intensity is part of the treatment. It is a fair and answerable question.

Ask whether another site in the system has supply. Large networks do not always have the same inventory at every location, and a drive can be worth more than a wait.

And if you are on a trial, ask now what happens to your access if supply is interrupted. The answer belongs in your file, not in your memory.

None of these questions make you a difficult patient. They make you a patient whose treatment plan is being tracked by two people instead of one — which, in a year when every major cancer center in the country is short of something, is not a bad arrangement.